PerkinElmer (NYSE:PKI) issued its quarterly earnings data on Tuesday. The medical research company reported $3.72 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.03 by $0.69, MarketWatch Earnings reports. PerkinElmer had a return on equity of 21.57% and a net margin of 12.74%. The company had revenue of $1.31 billion during the quarter, compared to analyst estimates of $1.18 billion. During the same quarter in the previous year, the company posted $0.67 earnings per share. PerkinElmer’s revenue was up 100.4% compared to the same quarter last year.

Shares of PKI traded down $2.75 during mid-day trading on Tuesday, reaching $127.81. The stock had a trading volume of 1,346,046 shares, compared to its average volume of 996,559. The firm has a market cap of $14.32 billion, a price-to-earnings ratio of 34.73, a PEG ratio of 0.99 and a beta of 1.19. PerkinElmer has a 12 month low of $88.27 and a 12 month high of $162.70. The business has a fifty day moving average of $130.77 and a 200 day moving average of $136.41. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.96 and a current ratio of 1.35.

The company also recently declared a quarterly dividend, which will be paid on Friday, August 6th. Shareholders of record on Friday, July 16th will be given a $0.07 dividend. The ex-dividend date is Thursday, July 15th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.22%. PerkinElmer’s payout ratio is currently 6.83%.

Several analysts recently commented on the company. Citigroup lifted their price objective on PerkinElmer from $150.00 to $155.00 in a report on Wednesday, February 3rd. Wells Fargo & Company raised PerkinElmer from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $140.00 to $175.00 in a report on Thursday, January 7th. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $133.93.

About PerkinElmer

PerkinElmer, Inc provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services.

Featured Story: Price to Earnings Ratio (PE)

Earnings History for PerkinElmer (NYSE:PKI)

Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with's FREE daily email newsletter.